In-Wha Kim

In-Wha Kim

Auto-generated profile, based on publicly available information

In-Wha Kim

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMinoh Ko
Minoh Ko
SKSunghwan Kim
Sunghwan Kim
SSSung Yun Suh
Sung Yun Suh
YCYoon Sook Cho
Yoon Sook Cho
IKIn-Wha Kim
In-Wha Kim
JOJung Mi Oh
Jung Mi Oh
(1) Background: A pharmacist-led deprescribing service previously developed within the Consultation-Based Palliative Care Team (CB-PCT) was implemented for terminal cancer patients. (2) Objective: To evaluate the clinical outcomes of the developed deprescribing service for terminal cancer patients in CB-PCT. (3) Methods: A retrospective analysis compared the active care (AC) group to the historical usual care (UC) group. The clinical outcomes included the deprescribing rate of preventive medications, the proportion of patients with one or more medication-related problems (MRPs) resolved upon discharge, and the clinical significance. The implementability of the service was also gauged by the acceptance rates of pharmacists’ interventions. (4) Results: Preventive medications included lipid-lowering agents, gastroprotective agents, vitamins, antihypertensives, and antidiabetic agents. The AC group revealed a higher deprescribing rate (10.4% in the UC group vs. 29.6% in the AC group, p < 0.001). At discharge, more AC patients had one or more MRPs deprescribed (39.7% vs. 2.97% in UC, p < 0.001). The clinical significance consistently had a very significant rating (mean score of 2.96 out of 4). Acceptance rates were notably higher in the AC group (30.0% vs. 78.0%. p = 0.003). (5) Conclusions: The collaborative deprescribing service in CB-PCT effectively identified and deprescribed MRPs that are clinically significant and implementable in practice.

21 November 2014 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
TKTherasa Kim
Therasa Kim
NHNayoung Han
Nayoung Han
MSMinji Sohn
Minji Sohn
JOJung Mi Oh
Jung Mi Oh
ELEui‐Kyung Lee
Eui‐Kyung Lee
IKIn‐Wha Kim
In‐Wha Kim

24 December 2024 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
HPHyun Jin Park
Hyun Jin Park
MKMinoh Ko
Minoh Ko
IKIn-Wha Kim
In-Wha Kim
JOJung Mi Oh
Jung Mi Oh
Background/Objectives: Taxanes, including paclitaxel and docetaxel, are widely used in cancer treatment but frequently cause hypersensitivity reactions (HSRs), disrupting treatment continuity. This meta-analysis aimed to identify consistent risk factors for taxane-induced HSRs to support personalized risk assessments and optimize therapeutic outcomes. Methods: This systematic review and meta-analysis followed the PRISMA guidelines and was registered with PROSPERO (CRD42023476738). Comprehensive literature searches were conducted up to 30 June 2024. The quality of the studies was assessed using the Newcastle-Ottawa Scale. Data were synthesized to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs), using fixed or random effects models. Results: A total of 18 studies of moderate or higher quality were included, involving 8333 patients. The incidence of HSRs ranged from 3.0% to 33.1%. Risk factors assessed included history of allergy, obesity, postmenopausal state, ovarian cancer, and H2 receptor antagonist (H2RA) premedication. A history of allergy was identified as a potential risk factor with marginal significance (OR 1.85, 95% CI 0.97–3.54, p = 0.06), while H2RA premedication, ovarian cancer, and female sex were not significantly associated with HSR risk. Substantial heterogeneity was observed for obesity (I2 = 57.71%, p = 0.069) and postmenopausal status (I2 = 78.98%). Conclusions: This study highlights the complex nature of taxane-induced HSRs and emphasizes the need for personalized risk assessments. While a history of allergy is a potential risk factor, heterogeneity across other factors underscores the importance of individualized approaches. Clinicians should tailor strategies to balance the benefits of taxane therapy with patient-specific risks to improve clinical outcomes.

14 June 2017 in Frontiers of Medicine
Verified
Journal Article
Closed access
PDF file
KKKyung Im Kim
Kyung Im Kim
SJSohyun Jeong
Sohyun Jeong
NHNayoung Han
Nayoung Han
JOJung Mi Oh
Jung Mi Oh
KOKook-Hwan Oh
Kook-Hwan Oh
IKIn-Wha Kim
In-Wha Kim

1 September 2017 in Biomolecules & Therapeutics
Verified
Journal Article
Open access
NHNayoung Han
Nayoung Han
YSYun-Kyoung Song
Yun-Kyoung Song
GBGilbert J. Burckart
Gilbert J. Burckart
EJEunhee Ji
Eunhee Ji
IKIn-Wha Kim
In-Wha Kim
JOJung Mi Oh
Jung Mi Oh
Individual differences in drug responses are associated with genetic and epigenetic variability of pharmacogene expression. We aimed to identify the relevant miRNAs which regulate pharmacogenes associated with drug responses. The miRNA and mRNA expression profiles derived from data for normal and solid tumor tissues in The Cancer Genome Atlas (TCGA) Research Network. Predicted miRNAs targeted to pharmacogenes were identified using publicly available databases. A total of 95 pharmacogenes were selected from cholangiocarcinoma and colon adenocarcinoma, as well as kidney renal clear cell, liver hepatocellular, and lung squamous cell carcinomas. Through the integration analyses of miRNA and mRNA, 35 miRNAs were found to negatively correlate with mRNA expression levels of 16 pharmacogenes in normal bile duct, liver, colon, and lung tissues (p<0.05). Additionally, 36 miRNAs were related to differential expression of 32 pharmacogene mRNAs in those normal and tumorigenic tissues (p<0.05). These results indicate that changes in expression levels of miRNAs targeted to pharmacogenes in normal and tumor tissues may play a role in determining individual variations in drug response.

31 December 2019 in Korean Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
MSMinji Sohn
Minji Sohn
YSYun-Kyoung Song
Yun-Kyoung Song
AJAh Young Jeon
Ah Young Jeon
JOJung Mi Oh
Jung Mi Oh
IKIn-Wha Kim
In-Wha Kim
Minji Sohn, Yun-Kyoung Song, Ah Young Jeon, Jung Mi Oh, and In-Wha Kim. Korean J Clin Pharm 2019;29:267-77. https://doi.org/10.24304/kjcp.2019.29.4.267